Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China
- PMID: 24165186
- PMCID: PMC3910797
- DOI: 10.1128/AAC.01228-13
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China
Abstract
China is one of the countries with the highest burdens of multidrug-resistant (MDR) and fluoroquinolone (FQ)-resistant tuberculosis (TB) globally. Nevertheless, knowledge about the prevalence and molecular characterization of FQ-resistant Mycobacterium tuberculosis isolates from this region remains scant. In this study, 138 M. tuberculosis isolates determined by the agar proportion susceptibility method to be resistant to ofloxacin (OFX) were enrolled from a national drug resistance survey of China. All these strains were tested for susceptibility to ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, and sparfloxacin using liquid Middlebrook 7H9 medium. The entire gyrA and gyrB genes conferring FQ resistance were sequenced, and spoligotyping was performed to distinguish different genotypes. Overall, the prevalence of resistance in China was highest for ofloxacin (3.76%), intermediate for levofloxacin (3.18%) and moxifloxacin (3.12%), and lowest for sparfloxacin (1.91%) and gatifloxacin (1.33%). Mutations in the gyrA gene were observed in 89 (64.5%) out of the 138 OFX-resistant M. tuberculosis strains. Positions 94 and 90 were the most frequent sites of mutation conferring FQ resistance on these strains, accounting for high-level FQ resistance. Furthermore, the Beijing genotype showed no association with high-level FQ resistance or distribution in hot spots in the quinolone resistance-determining region (QRDR) of gyrA. Our findings provide essential implications for the feasibility of genotypic tests relying on detection of mutations in the QRDR of gyrA and the shorter first-line treatment regimens based on FQs in China.
Similar articles
-
Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.Diagn Microbiol Infect Dis. 2012 Jul;73(3):260-3. doi: 10.1016/j.diagmicrobio.2012.03.025. Epub 2012 May 4. Diagn Microbiol Infect Dis. 2012. PMID: 22560167
-
Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.BMC Infect Dis. 2020 Jun 1;20(1):390. doi: 10.1186/s12879-020-05112-5. BMC Infect Dis. 2020. PMID: 32487030 Free PMC article.
-
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.J Med Microbiol. 2013 Jan;62(Pt 1):108-113. doi: 10.1099/jmm.0.046821-0. Epub 2012 Sep 27. J Med Microbiol. 2013. PMID: 23019190
-
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.J Antimicrob Chemother. 2010 Aug;65(8):1551-61. doi: 10.1093/jac/dkq202. Epub 2010 Jun 11. J Antimicrob Chemother. 2010. PMID: 20542907 Review.
-
The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis.Microbiol Spectr. 2014 Aug;2(4):MGM2-0009-2013. doi: 10.1128/microbiolspec.MGM2-0009-2013. Microbiol Spectr. 2014. PMID: 26104201 Review.
Cited by
-
Transmission of fluoroquinolones resistance among multidrug-resistant tuberculosis in Shanghai, China: a retrospective population-based genomic epidemiology study.Emerg Microbes Infect. 2024 Dec;13(1):2302837. doi: 10.1080/22221751.2024.2302837. Epub 2024 Jan 22. Emerg Microbes Infect. 2024. PMID: 38205528 Free PMC article.
-
Rapid detection of fluoroquinolone resistance in Mycobacterium tuberculosis using a novel multienzyme isothermal rapid assay.J Antibiot (Tokyo). 2023 Oct;76(10):598-602. doi: 10.1038/s41429-023-00639-6. Epub 2023 Jul 4. J Antibiot (Tokyo). 2023. PMID: 37402884
-
Genetic Characterization Conferred Co-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Isolates from Southern Xinjiang, China.Infect Drug Resist. 2023 May 19;16:3117-3135. doi: 10.2147/IDR.S407525. eCollection 2023. Infect Drug Resist. 2023. PMID: 37228658 Free PMC article.
-
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022. Front Public Health. 2022. PMID: 36620240 Free PMC article. Review.
-
Evaluation of whole-genome sequence to predict drug resistance of nine anti-tuberculosis drugs and characterize resistance genes in clinical rifampicin-resistant Mycobacterium tuberculosis isolates from Ningbo, China.Front Public Health. 2022 Aug 18;10:956171. doi: 10.3389/fpubh.2022.956171. eCollection 2022. Front Public Health. 2022. PMID: 36062095 Free PMC article.
References
-
- World Health Organization 2008. Anti-tuberculosis drug resistance in the world: fourth global report. WHO/HTM/TB/2008.394 World Health Organization, Geneva, Switzerland
-
- Yumo HA, Mbanya D, Kuaban C, Neuhann F. 2011. Outcome assessment of a Global Fund grant for tuberculosis control at the district level in rural Cameroon. Int. J. Tuberc. Lung Dis. 15:352–357 - PubMed
-
- Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, Hollm-Delgado MG, Keshavjee S, Deriemer K, Centis R, D'Ambrosio L, Lange C, Bauer M, Menzies D. 2013. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur. Respir. J. 42:156–168. 10.1183/09031936.00134712 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
